

## Appendix 3E

### Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

|                               |                |
|-------------------------------|----------------|
| Name of entity                | ABN/ARSN       |
| Sigma Pharmaceuticals Limited | 15 088 417 403 |

We (the entity) give ASX the following information.

#### Information about buy-back

|   |                                   |  |
|---|-----------------------------------|--|
| 1 | Type of buy-back                  | On-market buy-back   |
| 2 | Date Appendix 3C was given to ASX | 13 September 2012<br>(Associated Appendix 3D dated 4 October 2013) |

#### Total of all shares/units bought back, or in relation to which acceptances have been received, before, and on, previous day

|   | Before previous day  | Previous day             |
|---|--|--------------------------|
| 3 | Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received | 65,343,104<br>69,169     |
| 4 | Total consideration paid or payable for the shares/units   | \$46,483,896<br>\$40,754 |

**Appendix 3E**  
**Daily share buy-back notice**

---

|  | <b>Before previous day</b>                                      | <b>Previous day</b>  |
|--|---|--|
| 5 If buy-back is an on-market buy-back | Highest price paid: \$0.8525<br><br>Lowest price paid: \$0.5600 | Highest price paid: \$0.5900<br><br>Lowest price paid: \$0.5875<br><br>Highest price allowed under rule 7.33: \$0.6006 |

**How many shares/units may still be bought back?**

|   |            |
|---|------------|
| 6 If the company/trust has disclosed an intention to buy back a maximum number of shares/units – the remaining number of shares/units to be bought back | 53,218,079 |
|---|------------|

**Compliance statement**

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

*or, for trusts only:*

1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust’s constitution, relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:   
 2013  
 (Director/Company secretary)

Date: 26 November

Print name: Sue Morgan

=====  
 =====

---

